FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 217 filers reported holding FATE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.68 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $642,000 | +61.3% | 28,663 | +78.5% | 0.02% | +46.7% |
| Q2 2022 | $398,000 | +121.1% | 16,055 | +246.5% | 0.02% | +150.0% |
| Q1 2022 | $180,000 | +122.2% | 4,634 | +399.4% | 0.01% | +100.0% |
| Q2 2021 | $81,000 | +406.2% | 928 | +97.4% | 0.00% | +50.0% |
| Q2 2020 | $16,000 | +433.3% | 470 | +178.1% | 0.00% | +100.0% |
| Q3 2019 | $3,000 | -40.0% | 169 | -32.1% | 0.00% | 0.0% |
| Q2 2019 | $5,000 | – | 249 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |